Abstract
Mitochondrial dysfunction is associated with a number of human diseases. As an example, we recently established in vivo Drosophila models of IBMPFD (Inclusion body myopathy, Paget disease, and frontotemporal dementia), and uncovered that human disease mutations of the p97/VCP (Valosin Containing Protein) gene behave as hyperactive alleles associated with mitochondrial defects. Pharmacologic inhibition of VCP strongly suppressed disease and mitochondrial pathology in these animal models. In this protocol, we describe a method to evaluate mitochondrial respiratory function in IBMPFD patient-derived fibroblasts, as well as investigate the role of pharmacologic treatments. These experiments complement work done in animal models by investigating mitochondrial biology and the pharmacologic response in a human cell-based model of the disease. In principle, this technique can be used to investigate mitochondrial respiratory function for any disease in which patient-derived fibroblasts are available.
Original language | English (US) |
---|---|
Article number | e3446 |
Journal | Bio-protocol |
Volume | 9 |
Issue number | 23 |
DOIs | |
State | Published - Dec 5 2019 |
Externally published | Yes |
Keywords
- Inclusion body myopathy
- Mitochondrial respiration
- Paget disease and frontotemporal dementia (IBMPFD)
- Patient-derived fibroblasts
- Seahorse XF assay
- VCP/p97
ASJC Scopus subject areas
- General Neuroscience
- General Biochemistry, Genetics and Molecular Biology
- General Immunology and Microbiology
- Plant Science